Novosanis is a wholly owned subsidiary of OraSure Technologies Inc (NASDAQ: OSUR) and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology.
Novosanis launches Colli-Pee® containing UAS Large Volumes, offering a new solution for oncology research
Today, Novosanis has launched its novel solution for oncology research applications. Together with our sister company DNA Genotek, we have developed a novel stabilization chemistry, UAS TM , for the preservation of extracellular vesicle (EV) RNA, and cell-free DNA (cfDNA) in urine, collected with...
Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2022
Rotterdam, The Netherlands
Novosanis will be attending the Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2022 conference on March 1 & 2. The conference will focus on the development of liquid biopsies utilizing circulating cell-free DNA (cfDNA), circulating tumour cells (CTCs) and other biomarkers found in...